

<b>NCT ID</b>	NCT02499328
<b>Title</b>	Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2015-07-16
<b>Location</b>	Alabama, United States California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Belgium Germany Italy Spain United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Completed
<b>Drugs</b>	AZD5069, AZD9150, MEDI4736, tremelimumab (treme)
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT06107413
<b>Title</b>	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
<b>Phase</b>	Phase 2
<b>Date Added</b>	2023-10-30
<b>Location</b>	Arizona, United States Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States Oregon, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan South Korea Spain Taiwan
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting

<b>Drugs</b>	ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05425940
<b>Title</b>	Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303)
<b>Phase</b>	Phase 3
<b>Date Added</b>	2022-06-21
<b>Location</b>	Alabama, United States Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Belgium France Germany Hong Kong Hungary New Zealand Poland Portugal Singapore South Korea Spain Taiwan Thailand United Kingdom
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT05784688
<b>Title</b>	Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2023-03-27
<b>Location</b>	Texas, United States Washington, United States Korea, Republic of
<b>Prior IO Allowed</b>	No

<b>CRC-directed</b>	Yes
<b>Status</b>	Recruiting
<b>Drugs</b>	TU2218 + Pembrolizumab
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT03835949
<b>Title</b>	Study of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer
<b>Phase</b>	Phase 1
<b>Date Added</b>	2019-02-11
<b>Location</b>	Alabama, United States Arizona, United States California, United States Texas, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Atezolizumab, TJ004309
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT05350917
<b>Title</b>	Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
<b>Phase</b>	Phase 2
<b>Date Added</b>	2022-04-28
<b>Location</b>	
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Not yet recruiting
<b>Drugs</b>	Tislelizumab
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<b>NCT ID</b>	NCT03865082
<b>Title</b>	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
<b>Phase</b>	Phase 2
<b>Date Added</b>	2019-03-06
<b>Location</b>	Arizona, United States California, United States Texas, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	No
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy
<b>Tags</b>	MSS/ MMRp
<b>NCT ID</b>	NCT02869217
<b>Title</b>	Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
<b>Phase</b>	Phase 1
<b>Date Added</b>	2016-08-16
<b>Location</b>	Canada
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	No

<b>Status</b>	Active, not recruiting
<b>Drugs</b>	Cyclophosphamide, Fludarabine, TBI-1301
<b>Tags</b>	MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03223779
<b>Title</b>	Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2017-07-21
<b>Location</b>	Massachusetts, United States
<b>Prior IO Allowed</b>	Yes
<b>CRC-directed</b>	Yes
<b>Status</b>	Active, not recruiting
<b>Drugs</b>	
<b>Tags</b>	MSI-H/ MMRd, MSS/ MMRp
<hr/>	
<b>NCT ID</b>	NCT03711058
<b>Title</b>	Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
<b>Phase</b>	Phase 1, Phase 2
<b>Date Added</b>	2018-10-18
<b>Location</b>	Maryland, United States
<b>Prior IO Allowed</b>	No
<b>CRC-directed</b>	Yes
<b>Status</b>	Completed
<b>Drugs</b>	Copanlisib, Nivolumab
<b>Tags</b>	MSS/ MMRp